In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

All About Unlocking Eve: The Initiative Advancing Women In Healthcare Leadership

In Vivo's Chloe Kent discussed the future of women in healthcare leadership with Roche executives and Unlocking Eve founders Eva McLellan and Kaye Vitug.

Diversity & Inclusion Leadership Strategy

Regulators Keep Rare Diseases Open For Business

The cost of rare diseases to patients and society at large is 10 times higher than for many of the biggest mass market diseases combined. With 95% of rare diseases lacking a treatment or cure, there is an economic imperative for policymakers to keep encouraging pharmaceutical companies to develop more orphan drug treatments. In Vivo looks at the US and EU regulatory impetus to keep rare diseases open for innovation. 

Rare Diseases FDA Regulation

Putting The Patient First: The Challenge And Opportunities To Improve Rare-Disease Therapy Development


Advances in identifying the genetic causes of diseases, and particularly cancers, coupled with regulatory incentives to encourage the development of therapeutic approaches to once poorly managed orphan diseases have fueled a surge in exciting new medicines. To address some of these issues and explore potential solutions, Simbec-Orion in collaboration with Informa Pharma Intelligence convened a round table of experts attending the BIO International Convention

Read More

Growth Explore this Topic

Set Alert for Growth

Latest From Growth

Ways To Find And Nurture Young, Diverse Talent In Pharma

On this podcast, In Vivo's Jo Shorthouse is joined by Rebekah Martin, senior vice president of reward, inclusion, and talent acquisition at AstraZeneca to talk about the ways that pharma should be encouraging a diverse and inclusive team of young talent, and that strong connection between diversity of thought and innovation.

Diversity & Inclusion Strategy

Twist's Unconventional Approach, Adding Value One Rung At A Time

Building a narrow set of products and services that provide reliable and consistent revenue is a perfectly sound business strategy and one that sustains many biotech companies. But for the hungrier, like Twist Bioscience, Inc., a strategy of ongoing disruption and evolution has been more appealing and indeed is generating significant growth. Emily Leproust, Twist’s CEO, spoke with In Vivo about what it means to follow a value-added business strategy.

Business Strategies Commercial

Deerfield Management On Fund Building, Philanthropy, And Optimism For The Future

Andrew ElBardissi, partner on Deerfield Management’s medical technologies team, spoke to In Vivo sister publication Medtech Insight about the fund’s investment strategy, the changing face of medtech, and how investment in the life sciences sector will continue to change post-COVID.

Financing Deals

Innovation Explore this Topic

Set Alert for Innovation

Latest From Innovation

Snapshot: September Highlights

A selection of articles you might have missed from September 2022, including highlights from In Vivo's spotlight on rare diseases, their diagnosis and treatment.

Rare Diseases Regulation

Seven Potential Blockbuster Approvals To Look Out For In 2023

After highlighting oncology drugs pegged to make a splash next year with the help of Biomedtracker, Scrip takes a look at seven potential blockbusters across a range of therapeutic areas including neurology, dermatology and blood disorders slated for approval next year.

Approvals Companies

The Compelling Investment Case Of Rare Diseases

Rare diseases are an underserved target for innovation, but development and commercialization hurdles can be staggering.

Rare Diseases Commercial
Data Spotlight

Financing Quarterly Statistics, Q2 2022

During Q2, biopharmas brought in an aggregate $12.5bn in financing and device company fundraising totaled $3.7bn; while in vitro diagnostic firms and research tools players raised $720m.

Pandemic Windfall Upends Status Quo For Top-10 Best-Selling Drugs

This article reveals the top 10 pharmaceutical products by revenues in 2022 and discusses the major themes affecting the highest-grossing drugs and the companies behind their continued development.

Titans Of Pharma 2022: Johnson & Johnson Pays Highest Exec Compensation Again

Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.

Leadership Explore this Topic

Set Alert for Leadership

Latest From Leadership

Ways To Find And Nurture Young, Diverse Talent In Pharma

On this podcast, In Vivo's Jo Shorthouse is joined by Rebekah Martin, senior vice president of reward, inclusion, and talent acquisition at AstraZeneca to talk about the ways that pharma should be encouraging a diverse and inclusive team of young talent, and that strong connection between diversity of thought and innovation.

Diversity & Inclusion Strategy

Snapshot: September Highlights

A selection of articles you might have missed from September 2022, including highlights from In Vivo's spotlight on rare diseases, their diagnosis and treatment.

Rare Diseases Regulation

Insmed CEO On Innovating To Compete In Rare Disease

Leading the company with the only therapy approved for NTM lung disease, Will Lewis tells In Vivo that success comes from giving researchers room to breath, visualizing patient benefit, and sailing into uncharted waters.

Innovation Rare Diseases

Market Access Explore this Topic

Set Alert for Market Access

Latest From Market Access

Mifepristone Access Swings In The Balance In Post-Roe World

The US Supreme Court has overturned Roe v. Wade, but numerous avenues could help to preserve access to abortion drug mifepristone – if legislators and lawmakers are willing to walk down them.

FDA Legal Issues

Re-Thinking Rare Disease

Germany is drastically squeezing orphan drug pricing while new US laws protect rare diseases drugs from price negotiations. These contrasting moves fuel the longstanding debate over whether orphans still deserve special incentives.

Cost Effectiveness Rare Diseases

Argenx CEO Shares Secrets Of Vyvgart’s Stellar Success

Leaving commercial hires to just a few months before drug approval is a mistake, Argenx CEO Tim Van Hauwermeiren told In Vivo sister publication Scrip, noting that the impressive launch achieved for Vyvgart for generalized myasthenia gravis in the US and Japan will be a steadier affair in Europe.

Launches Business Strategies

Market Intelligence Explore this Topic

Set Alert for Market Intelligence

Latest From Market Intelligence

Decentralized Trials Are Here To Stay; What Challenges Do They Face?

Decentralized trials took a leap in popularity over the past few years, in part thanks to the COVID-19 pandemic. In Vivo's sister publication Medtech Insight spoke to two executives at clinical research technology companies about running decentralized clinical trials to discuss the benefits and limitations of trials run remotely.

Clinical Trials Digital Health

The Role Of Patient Advocacy Organizations In Regulatory Best Practice

The most recent FDA guidance on the use of real-world data in regulatory decision making is fundamental for patient advocacy organizations, ensuring that the FDA endorses drugs or biological products that lead to proper health outcomes without the risk of life-threatening side effects. 

FDA Regulation

Deals In Depth: August 2022

The height of the summer saw eight $1bn plus deals penned, including those by Pfizer and Roche.

Deals Financing
UsernamePublicRestriction

Register